| Name | Title | Contact Details |
|---|---|---|
Charles Marra |
Vice President of Technology | Profile |
Nick Gianadda |
Chief Technology Officer | Profile |
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.
Lifeprint is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMx is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.